Clinical Collaboration The company is actively expanding clinical development efforts in radiopharmaceuticals with leadership additions such as a Chief Medical Officer, suggesting opportunities to offer clinical research services, regulatory support, and trial management solutions to accelerate development timelines.

SNMMI Engagement Participation in SNMMI 2026 and presentation of clinical data imply a need for scientific communications, conference logistics support, and potential partnerships for data analytics or investigator-initiated trials to broaden market reach.

Strategic Partnerships Past collaborations with Brookline Capital Markets and industry-focused partners indicate openness to third-party alliances; there may be opportunities to provide advisory services, capital market readiness, or manufacturing and supply chain collaboration for radiopharmaceuticals.

Operations Scale Small team size combined with venture-style growth signals a demand for scalable cloud-based workflows, compliance tooling, and outsourced R&D support to expand capabilities without proportionally increasing headcount.

Market Positioning As a clinical-stage radiopharmaceutical company with revenue under one million, there is potential to sell regulatory, quality assurance, clinical data management, and CRO-style services to accelerate clinical milestones and attract potential investors.